Rectify develops Positive Functional Modulators (PFMs), a novel class of oral, small molecules that restore and enhance membrane protein function to address the underlying cause of serious diseases. PFMs have the potential to modulate the activity of wild-type and mutated membrane bound proteins. The Rectify platform enables efficient and rapid discovery of first- and best-in-class small molecule therapeutic candidates for the treatment of rare and common diseases, including liver, cardio-renal-metabolic, and neurodegenerative diseases. Rectify was founded and seeded by Atlas Venture who co-led the $100M Series A round with Omega Funds and were joined by Forbion and Longwood Fund.
Company Details
- Employees
- 24
- Founded
- -
- Address
- Boston, Ma, Us
- Industry
- Biotechnology
- Website
- https://rectifypharma.com/
- HQ
- Boston, MA
Rectify Pharma Questions
Rectify Pharma's website is https://rectifypharma.com/
Rectify Pharma's LinkedIn profile is https://www.linkedin.com/company/rectify-pharma
Rectify Pharma has
24 employees.
View email and phone details for 24
employees at Rectify Pharma.
Rectify Pharma's industry is
Biotechnology
Rectify Pharma's top competitors are
Atlas Venture,
Mural Oncology,
Dyne Therapeutics,
Verve Therapeutics,
Scholar Rock,
Akouos,
Ring Therapeutics,
Vesalius Therapeutics,
Disc Medicine,
Generation Bio.
Rectify Pharma's categories are Biotechnology
Rectify Pharma's founding year is 2020
